About Surrozen, Inc.
https://www.surrozen.comSurrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
CEO
Craig C. Parker
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-12-14 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
CONSONANCE CAPITAL MANAGEMENT LP
Shares:3.5M
Value:$69.95M
STEMPOINT CAPITAL LP
Shares:713.46K
Value:$14.27M
VR ADVISER, LLC
Shares:632.93K
Value:$12.66M
Summary
Showing Top 3 of 41
About Surrozen, Inc.
https://www.surrozen.comSurrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $983K | $11.87M ▲ | $-71.64M ▼ | -7.29K% ▼ | $-8.36 ▼ | $-71.58M ▼ |
| Q2-2025 | $983K | $10M ▼ | $39.75M ▲ | 4.04K% ▲ | $2.55 ▲ | $-8.88M ▲ |
| Q1-2025 | $983K ▲ | $10.53M ▲ | $-26.97M ▲ | -2.74K% ▲ | $-7.43 ▲ | $-9.26M ▼ |
| Q4-2024 | $655K ▼ | $9.25M ▲ | $-28.04M ▼ | -4.28K% ▼ | $-9 ▼ | $-8.27M ▼ |
| Q3-2024 | $10M | $8.77M | $-1.43M | -14.34% | $-0.44 | $1.57M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $81.33M ▼ | $94.05M ▼ | $117.56M ▲ | $-23.52M ▼ |
| Q2-2025 | $90.39M ▼ | $102.7M ▼ | $55.58M ▼ | $47.11M ▲ |
| Q1-2025 | $101.64M ▲ | $114.83M ▲ | $109.16M ▲ | $5.67M ▲ |
| Q4-2024 | $34.56M ▲ | $48.47M ▲ | $69.85M ▲ | $-21.38M ▼ |
| Q3-2024 | $31.01M | $48M | $42.33M | $5.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-71.64M ▼ | $-9.04M ▼ | $-24K ▼ | $9K ▲ | $-9.05M ▲ | $-9.06M ▼ |
| Q2-2025 | $39.75M ▲ | $-6.11M ▲ | $-18K ▲ | $-5.12M ▼ | $-11.26M ▼ | $-6.13M ▲ |
| Q1-2025 | $-26.97M ▲ | $-9.28M ▼ | $-27K ▼ | $76.39M ▲ | $67.08M ▲ | $-9.31M ▼ |
| Q4-2024 | $-28.04M ▼ | $3.48M ▲ | $-19K ▼ | $91K ▲ | $3.55M ▲ | $3.46M ▲ |
| Q3-2024 | $-1.43M | $-6.75M | $0 | $-1K | $-6.75M | $-6.75M |
Revenue by Geography
| Region | Q1-2025 | Q2-2025 |
|---|---|---|
 UNITED STATES | $0 ▲ | $0 ▲ |
CEO
Craig C. Parker
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-12-14 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
CONSONANCE CAPITAL MANAGEMENT LP
Shares:3.5M
Value:$69.95M
STEMPOINT CAPITAL LP
Shares:713.46K
Value:$14.27M
VR ADVISER, LLC
Shares:632.93K
Value:$12.66M
Summary
Showing Top 3 of 41